Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China.
Neuroendocrinology. 2012;96(4):333-42. doi: 10.1159/000339823. Epub 2012 Aug 28.
Previous studies attempting to define the natural history of postoperative nonfunctioning pituitary adenomas (pNFPAs) were somewhat limited by selection bias and/or small numbers and/or lack of consistency among the study findings. The aim of this study was to scrutinize the literature in order to analyze the natural history of pNFPAs.
Electronic database including MEDLINE, PubMed and Cochrane CENTRAL were searched. The literature relating to the patients with pNFPAs without postoperative radiotherapy and pharmacotherapy was collected. Eligible studies reported on the rate of tumor recurrence, the tumor growth-free survival rate (TGFSR) at 5 and 10 years, and/or the residual tumor volume doubling time (TVDT).
19 studies met the criteria. The pNFPAs were divided into two groups: the pooled recurrence rate of group I without detectable residual tumor (371 patients) was 12% (95% CI 6-19%), the TGFSR at 5 and 10 years were 96% (95% CI 89-99%) and 82% (95% CI 65-94%), respectively. The pooled recurrence rate of group II with residual tumor (600 patients) was 46% (95% CI 36-56%), the TGFSR at 5 and 10 years were 56% (95% CI 41-71%) and 40% (95% CI 27-53%), respectively. The mean TVDT was 3.4 years (95% CI 2.4-4.5 years).
pNFPAs, with or without detectable residual tumor, need stratification of treatment and radiological/endocrinological follow-up strategy. According to the TVDT, residual tumor regrowth is very slow, which permits an extensive and safe follow-up program for most patients.
之前试图定义术后无功能垂体腺瘤(pNFPAs)自然史的研究受到选择偏倚和/或数量较少和/或研究结果缺乏一致性的限制。本研究的目的是仔细审查文献,以分析 pNFPAs 的自然史。
检索电子数据库包括 MEDLINE、PubMed 和 Cochrane CENTRAL。收集了与未接受术后放疗和药物治疗的 pNFPAs 患者相关的文献。符合条件的研究报告了肿瘤复发率、5 年和 10 年肿瘤无进展生存率(TGFSR)和/或残留肿瘤体积倍增时间(TVDT)。
19 项研究符合标准。将 pNFPAs 分为两组:无残留肿瘤的 I 组(371 例)的总复发率为 12%(95%CI 6-19%),5 年和 10 年 TGFSR 分别为 96%(95%CI 89-99%)和 82%(95%CI 65-94%)。有残留肿瘤的 II 组(600 例)的总复发率为 46%(95%CI 36-56%),5 年和 10 年 TGFSR 分别为 56%(95%CI 41-71%)和 40%(95%CI 27-53%)。平均 TVDT 为 3.4 年(95%CI 2.4-4.5 年)。
有或无残留肿瘤的 pNFPAs 需要分层治疗和影像学/内分泌学随访策略。根据 TVDT,残留肿瘤的再生长非常缓慢,这允许为大多数患者制定广泛而安全的随访计划。